Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,591.60INR
14 Dec 2018
Change (% chg)

Rs-4.50 (-0.17%)
Prev Close
Rs2,596.10
Open
Rs2,624.90
Day's High
Rs2,624.90
Day's Low
Rs2,569.00
Volume
24,052
Avg. Vol
72,263
52-wk High
Rs2,745.00
52-wk Low
Rs1,888.00

Latest Key Developments (Source: Significant Developments)

Indivior Says Federal Court Declines Immediate Issue Of Mandate
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Indivior PLC ::FEDERAL COURT DECLINES IMMEDIATE ISSUE OF MANDATE.COURT OF APPEALS FOR FEDERAL CIRCUIT DECLINES TO IMMEDIATELY ISSUE MANDATE AFTER PRELIMINARY INJUNCTION RULING.U.S. COURT DENIED DR. REDDY'S MOTION TO IMMEDIATELY ISSUE MANDATE FOLLOWING CAFC'S RULING VACATING PRELIMINARY INJUNCTION.CAFC ALSO ORDERED THAT ANY PETITION FOR REHEARING BE SUBMITTED ON OR BEFORE DECEMBER 20, 2018.REDDY'S WILL REMAIN ENJOINED FROM RESUMING "AT-RISK" U.S. LAUNCH OF GENERIC BUPRENORPHINE-NALOXONE SUBLINGUAL FILM TILL AFTER MANDATE ISSUES.  Full Article

Dr.Reddy's Laboratories Launches Chlorthalidone Tablets, USP In U.S. Market
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Dr.Reddy's Laboratories Ltd ::SAYS ANNOUNCES LAUNCH OF CHLORTHALIDONE TABLETS, USP IN U.S. MARKET.  Full Article

Indivior Responds To Court Decision Related To Dr. Reddy's Laboratories
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Indivior PLC ::INDIVIOR RESPONDS TO FEDERAL COURT DECISION.SAYS FY 2018 GUIDANCE REMAINS VALID UNTIL SUCH TIME A GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM ENTERS MARKET IN 2018.SAYS WILL CONTINUE TO DEFEND ITS INTELLECTUAL PROPERTY AND IMPLEMENT CONTINGENCY PLAN.  Full Article

Indivior Says Court Lifts Injunction Barring Dr. Reddy's From Selling Generic Version Of Suboxone
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Indivior PLC ::INDIVIOR PLC - INDIVIOR MAKES STATEMENT ON COURT DECISION.INDIVIOR PLC - DISAPPOINTED THAT U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT HAS VACATED PRELIMINARY INJUNCTION AGAINST DR. REDDY'S LABORATORIES.INDIVIOR PLC - IN PROCESS OF INTERPRETING RULING IN ITS ENTIRETY AND WILL ISSUE A STATEMENT ON ITS IMPLICATIONS ONCE THIS REVIEW HAS BEEN COMPLETED.INDIVIOR PLC - WILL CONTINUE TO PURSUE ONGOING INFRINGEMENT CASES AGAINST DRL TO PROTECT SUBOXONE SUBLINGUAL FILM PATENT PORTFOLIO.  Full Article

Indivior Says Perseris Now Available In U.S. For Treatment Of Schizophrenia In Adults
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Indivior PLC ::INDIVIOR PLC - PERSERIS(TM) AVAILABILITY.INDIVIOR - FIRST ONCE-MONTHLY RISPERIDONE-CONTAINING SUBCUTANEOUS LONG-ACTING INJECTABLE, AVAILABLE IN U.S. FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS.INDIVIOR PLC - PERSERIS IS APPROVED BY U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS.INDIVIOR PLC - ANTICIPATING, AND PREPARING FOR, A FULL PROMOTIONAL LAUNCH BY SALESFORCE FOR PERSERIS IN FEBRUARY 2019.INDIVIOR- LAUNCH FOR PERSERIS CONTINGENT ON U.S. COURT UPHOLDING PRELIMINARY INJUNCTION ON GENERIC BUPRENORPHINE, NALOXONE FILM AGAINST DR REDDY'S.  Full Article

Dr.Reddy's Laboratories Says USFDA Audit Of Formulations Plant In Andhra Pradesh Completed With Zero Observations
Friday, 16 Nov 2018 

Nov 16 (Reuters) - Dr.Reddy's Laboratories Ltd ::AUDIT OF FORMULATIONS SRIKAKULUM PLANT (SEZ) UNIT II, ANDHRA PRADESH BY USFDA, COMPLETED WITH ZERO OBSERVATIONS.  Full Article

Dr.Reddy's Laboratories Says Regulatory Authority Of Germany Concluded Follow-On Audit Of Co's Duvvada Facility
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Dr.Reddy's Laboratories Ltd ::ON NOV 9, REGULATORY AUTHORITY OF GERMANY CONCLUDED FOLLOW-ON AUDIT OF CO'S FORMULATIONS MANUFACTURING FACILITY IN DUVVADA.FACILITY IS CONSIDERED COMPLIANT & EU-GMP CERTIFICATION CONTINUES TO REMAIN ACTIVE WITH 1 SPECIFIC EXCLUSION OF A NEW PRODUCT.SAYS CO WILL BE SUBMITTING A DETAILED CORRECTIVE AND PREVENTIVE ACTION PLAN (CAPA) TO AUTHORITIES.  Full Article

Dr.Reddy's Labs Launches Atomoxetine Capsules, USP In U.S. Market
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Dr.Reddy's Laboratories Ltd ::SAYS LAUNCH OF ATOMOXETINE CAPSULES, USP IN THE U.S. MARKET.  Full Article

India's Dr.Reddy's Laboratories Sept-Qtr Consol Profit Up About 70 Pct
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Dr.Reddy's Laboratories Ltd ::SEPT QUARTER CONSOL PAT 5.20 BILLION RUPEES - TV.CONSENSUS FORECAST FOR SEPT QUARTER CONSOL PROFIT WAS 3.52 BILLION RUPEES.SEPT QUARTER CONSOL NET PROFIT 5.18 BILLION RUPEES VERSUS PROFIT OF 3.05 BILLION RUPEES LAST YEAR.SEPT QUARTER CONSOL NET SALES 36.87 BILLION RUPEES VERSUS 34.91 BILLION RUPEES LAST YEAR.THE FIRST PROFIT ALERT WAS SOURCED FROM TELEVISION.  Full Article

Dr.Reddy's Laboratories Launches Colesevelam Hydrochloride Tablets In U.S.
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - Dr.Reddy's Laboratories Ltd ::LAUNCHES COLESEVELAM HYDROCHLORIDE TABLETS IN THE U.S. MARKET.  Full Article

REFILE-UPDATE 1-Indivior wins fresh hold on Dr. Reddy's Suboxone copy

Dec 12 Indivior Plc has secured another hold on the launch of a generic competitor to its best-selling opioid addiction drug in the United States, the London-listed company said on Wednesday.